In the fall of 2019, Vertex launched Trikafta, the latest of its breakthrough therapies for people with cystic fibrosis. Capable of treating up to 90% of those who suffer from the progressive, life-threatening disease, the drug has already been used to treat thousands of patients in the U.S. and recently won approval in the EU. The company’s sales—$4.2 billion in 2019—have averaged 35% annual growth over the past three years. One setback: The biotech’s stock fell 23% in October after it scrapped a new drug in Phase II clinical trials.

Courtesy of Vertex

Company Information

As of 5/23/2022
Country
U.S.
Headquarters
Boston
Industry
Pharmaceuticals
CEO
Reshma Kewalramani
Company Type
Public
Ticker
VRTX
Revenues ($M)
$7,574.4
Profits ($M)
$2,342.1
Market Value ($M)
$66,436.9
Employees
3,900
Market value as of March 31, 2022.

Future 50
As of 12/3/20

Overall Score
2
Sector
Health Care

Historical Data

YearRevenues ($M)Profits ($M)
2019$3,454$2,215
2018$2,623$415
FortuneDataStore ad
Lists ranking Vertex Pharmaceuticals
RANK448
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MORE
RANK4
Best Workplaces in Biotechnology and Pharmaceuticals - 2022...READ MORE
RANK82
100 Best Workplaces for Women - 2022...READ MORE